Survey Shows Strong Preference for Lomitapide Over Mipomersen
Available for Download at http://lifesciadvisors.com/marketresearch/
NEW YORK, NY – July 2, 2012 – LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 39 practicing lipidologists who answered on their expected use of Aegerion Pharmaceuticals’ lomitapide and Isis Pharmaceuticals’ mipomersen in patients with Homozygous Familial Hypercholesterolemia (HoFH) or “uncontrollably” high LDL levels, should these two new drugs get approved by the FDA.
“Based on the results of our proprietary survey of lipidologists, we believe there is much stronger interest in the use of lomitapide over mipomersen for the treatment of patients with extremely high and uncontrollable cholesterol levels,” said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. “The 39 survey responders intend to prescribe lomitapide to a total of 254 patients and mipomersen to a total of 152 patients. “Regarding efficacy, 44% of the responders view lomitapide as very efficacious compared to 13% for mipomersen. Regarding safety, 62% of the responders view lomitapide as moderately safe compared to 43% for mipomersen.“
Lomitapide, a microsomal triglyceride protein inhibitor, is a once-daily pill being developed by Aegerion Pharmaceuticals for the HoFH indication. It has a PDUFA data of December 29, 2012. Aegerion holds exclusive worldwide rights to lomitapide. Mipomersen is an apolipoprotein-B (apo-B) synthesis inhibitor co-developed by Isis and Genzyme, which has a January 29, 2013 PDUFA date for the HoFH indication.
